Biopharma firm CorMedix's Q2 revenue beats estimates, announces acquisition of Melinta Therapeutics

CorMedix

07/08/2025 12:32

Overview

CorMedix Q2 2025 rev of $39.7 mln beats analyst expectations, per LSEG data

EPS for Q2 2025 beats consensus, driven by DefenCath sales, per LSEG data

Co announces acquisition of Melinta Therapeutics, closing expected by Sept 1, 2025

Outlook

Company expects sufficient resources to fund operations for at least 12 months

CorMedix anticipates closing Melinta acquisition by September 1, 2025

Result Drivers

DEFENCATH SALES - Significant increase in DefenCath sales drove Q2 2025 revenue growth, per company

OPERATING EXPENSES - Rise in operating expenses due to increased G&A and R&D costs, per company

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$39.70 mln
$34 mln (7 Analysts)
Q2 EPS
Beat
$0.28
$0.17 (7 Analysts)
Q2 Net Income
Beat
$19.80 mln
$12 mln (6 Analysts)
Q2 Basic EPS
$0.29
Q2 Operating Expenses
$18.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for CorMedix Inc is $20.00, about 40.3% above its August 6 closing price of $11.95

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nGNX4Fdrl4

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)